Engineering bispecific HER2xVEGF designed ankyrin repeat proteins for targeted nanobiotechnology applications.

ABSTRACT:

Background

Targeting both tumor cell surface receptors and soluble pro-angiogenic factors is a promising strategy to improve cancer treatment specificity and reduce therapy resistance. Human epidermal growth factor receptor 2 (HER2) and vascular endothelial growth factor (VEGF) are two clinically validated targets implicated in tumor growth, metastasis, and angiogenesis. To address limitations of conventional large-molecule therapeutics, we developed a modular bispecific protein scaffold based on Designed Ankyrin Repeat Proteins (DARPins) for precision nanobiotechnology applications.

Results

We engineered a bispecific HER2×VEGF DARPin containing a C-terminal cysteine for site-specific bioorthogonal conjugation. The construct was recombinantly expressed in Escherichia coli an

SUBMITTER: Chen F 

PROVIDER: S-EPMC12495870 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature